Compare $INAB vs $KPTI | Chartloom

Compare

$INAB vs $KPTI

IN8bio Inc · Karyopharm Therapeutics Inc

INAB

IN8bio Inc

KPTI

Karyopharm Therapeutics Inc

Compare $INAB vs $KPTI

Comparing IN8bio Inc and Karyopharm Therapeutics Inc

INABIN8bio Inc

KPTIKaryopharm Therapeutics Inc

INABIN8bio Inc

Market cap

$13M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-45.5%

52W performance

-44.4%

FCF yield

-110.6%

KPTIKaryopharm Therapeutics Inc

Market cap

$14M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.10x

Rev growth (TTM)

6.8%

YTD performance

-91.6%

52W performance

-89.7%

FCF yield

-476.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

INAB

KPTI

Detailed metrics comparison

INAB

IN8bio Inc

KPTI

Karyopharm Therapeutics Inc

Market Cap

INAB$13M

KPTI$14M

Enterprise Value

INAB$-5M

KPTI$281M

Price

INAB$1.34

KPTI$0.61

P/E Ratio

INABN/A

KPTIN/A

P/S Ratio

INAB0.00x

KPTI0.09x

EV/Sales

INAB0.00x

KPTI1.92x

EV/EBITDA

INAB0.00x

KPTI0.00x

P/B Ratio

INAB0.75x

KPTI0.36x

P/FCF Ratio

INABN/A

KPTIN/A

EV/FCF

INAB0.32x

KPTI-4.30x

PEG Ratio

INABN/A

KPTIN/A

Forward P/E (NTM)

INABN/A

KPTIN/A

Forward P/S (NTM)

INABN/A

KPTI0.10x

Revenue (TTM)

INAB$0

KPTI$147M

Revenue Growth (YoY)

INABN/A

KPTI6.8%

Forward Rev Growth

INAB1211.4%

KPTI27.7%

Gross Margin (TTM)

INAB0.0%

KPTI95.9%

Operating Margin (TTM)

INAB0.0%

KPTI0.0%

EBITDA Margin (TTM)

INAB0.0%

KPTI-56.1%

Net Margin (TTM)

INAB0.0%

KPTI-153.3%

FCF Margin (TTM)

INABN/A

KPTI-44.6%

Net Income (TTM)

INAB$-19M

KPTI$-225M

FCF (TTM)

INAB$-15M

KPTI$-65M

EPS (TTM)

INAB-$0.96

KPTI-$7.77

ROE (TTM)

INAB-9118.0%

KPTI-18243.0%

ROA (TTM)

INAB-7693.0%

KPTI-20094.0%

ROIC (TTM)

INAB-9006.0%

KPTI-6632.0%

Cash

INAB$18M

KPTI$55M

Debt

INAB$126K

KPTI$322M

Net Cash/Debt

INAB$18M

KPTI$-267M

Current Ratio (TTM)

INAB8.21x

KPTI0.79x

Quick Ratio (TTM)

INAB8.13x

KPTI0.71x

Debt/Equity (TTM)

INAB0.01x

KPTI3.78x

Debt/Assets (TTM)

INAB0.0%

KPTI0.0%

Interest Coverage (TTM)

INABN/A

KPTIN/A

Net Debt/EBITDA (TTM)

INAB0.00x

KPTI0.00x

Beta

INAB0.24

KPTI1.14

52W Performance

INAB-44.4%

KPTI-89.7%

YTD Performance

INAB-45.5%

KPTI-91.6%

% from 52W High

INAB-50.9%

KPTI-94.5%

% from 52W Low

INAB52.3%

KPTI7.1%

Asset Turnover (TTM)

INAB0.00x

KPTI1.31x

FCF Yield (TTM)

INAB-110.6%

KPTI-476.7%

Earnings Yield (TTM)

INAB-141.4%

KPTI-1639.3%

Dividend Yield (TTM)

INABN/A

KPTIN/A

Rule of 40

INAB0.0

KPTI-37.8

EV/GP/RG

INABN/A

KPTI0.07

Ticker research

View INAB research View KPTI research

Metric	INAB IN8bio Inc	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$13M	$14M
Enterprise Value	$-5M	$281M
Price	$1.34	$0.61
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.09x
EV/Sales	0.00x	1.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.75x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	0.32x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.10x
Revenue & Growth
Revenue (TTM)	$0	$147M
Revenue Growth (YoY)	N/A	6.8%
Forward Rev Growth	1211.4%	27.7%
Profitability
Gross Margin (TTM)	0.0%	95.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-56.1%
Net Margin (TTM)	0.0%	-153.3%
FCF Margin (TTM)	N/A	-44.6%
Net Income (TTM)	$-19M	$-225M
FCF (TTM)	$-15M	$-65M
EPS (TTM)	-$0.96	-$7.77
ROE (TTM)	-9118.0%	-18243.0%
ROA (TTM)	-7693.0%	-20094.0%
ROIC (TTM)	-9006.0%	-6632.0%
Financial Health
Cash	$18M	$55M
Debt	$126K	$322M
Net Cash/Debt	$18M	$-267M
Current Ratio (TTM)	8.21x	0.79x
Quick Ratio (TTM)	8.13x	0.71x
Debt/Equity (TTM)	0.01x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.24	1.14
52W Performance	-44.4%	-89.7%
YTD Performance	-45.5%	-91.6%
% from 52W High	-50.9%	-94.5%
% from 52W Low	52.3%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.31x
FCF Yield (TTM)	-110.6%	-476.7%
Earnings Yield (TTM)	-141.4%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View INAB research	View KPTI research

Valuation

P/S Ratio

INAB

0.00x

KPTI

0.09x

EV/FCF

KPTI

-4.30x

INAB

0.32x

Growth & revenue

Revenue Growth TTM

KPTI

6.8%

Forward Revenue Growth

INAB

1211.4%

KPTI

27.7%

Profitability & performance

Gross Margin

KPTI

95.9%

INAB

0.0%

ROE

INAB

-9118.0%

KPTI

-18243.0%

FCF Yield %

INAB

-110.6%

KPTI

-476.7%

52-Week Performance

INAB

-44.4%

KPTI

-89.7%

Detailed metrics comparison

INAB

IN8bio Inc

KPTI

Karyopharm Therapeutics Inc

Market Cap

INAB$13M

KPTI$14M

Enterprise Value

INAB$-5M

KPTI$281M

Price

INAB$1.34

KPTI$0.61

P/E Ratio

INABN/A

KPTIN/A

P/S Ratio

INAB0.00x

KPTI0.09x

EV/Sales

INAB0.00x

KPTI1.92x

EV/EBITDA

INAB0.00x

KPTI0.00x

P/B Ratio

INAB0.75x

KPTI0.36x

P/FCF Ratio

INABN/A

KPTIN/A

EV/FCF

INAB0.32x

KPTI-4.30x

PEG Ratio

INABN/A

KPTIN/A

Forward P/E (NTM)

INABN/A

KPTIN/A

Forward P/S (NTM)

INABN/A

KPTI0.10x

Revenue (TTM)

INAB$0

KPTI$147M

Revenue Growth (YoY)

INABN/A

KPTI6.8%

Forward Rev Growth

INAB1211.4%

KPTI27.7%

Gross Margin (TTM)

INAB0.0%

KPTI95.9%

Operating Margin (TTM)

INAB0.0%

KPTI0.0%

EBITDA Margin (TTM)

INAB0.0%

KPTI-56.1%

Net Margin (TTM)

INAB0.0%

KPTI-153.3%

FCF Margin (TTM)

INABN/A

KPTI-44.6%

Net Income (TTM)

INAB$-19M

KPTI$-225M

FCF (TTM)

INAB$-15M

KPTI$-65M

EPS (TTM)

INAB-$0.96

KPTI-$7.77

ROE (TTM)

INAB-9118.0%

KPTI-18243.0%

ROA (TTM)

INAB-7693.0%

KPTI-20094.0%

ROIC (TTM)

INAB-9006.0%

KPTI-6632.0%

Cash

INAB$18M

KPTI$55M

Debt

INAB$126K

KPTI$322M

Net Cash/Debt

INAB$18M

KPTI$-267M

Current Ratio (TTM)

INAB8.21x

KPTI0.79x

Quick Ratio (TTM)

INAB8.13x

KPTI0.71x

Debt/Equity (TTM)

INAB0.01x

KPTI3.78x

Debt/Assets (TTM)

INAB0.0%

KPTI0.0%

Interest Coverage (TTM)

INABN/A

KPTIN/A

Net Debt/EBITDA (TTM)

INAB0.00x

KPTI0.00x

Beta

INAB0.24

KPTI1.14

52W Performance

INAB-44.4%

KPTI-89.7%

YTD Performance

INAB-45.5%

KPTI-91.6%

% from 52W High

INAB-50.9%

KPTI-94.5%

% from 52W Low

INAB52.3%

KPTI7.1%

Asset Turnover (TTM)

INAB0.00x

KPTI1.31x

FCF Yield (TTM)

INAB-110.6%

KPTI-476.7%

Earnings Yield (TTM)

INAB-141.4%

KPTI-1639.3%

Dividend Yield (TTM)

INABN/A

KPTIN/A

Rule of 40

INAB0.0

KPTI-37.8

EV/GP/RG

INABN/A

KPTI0.07

Ticker research

View INAB research View KPTI research

Metric	INAB IN8bio Inc	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$13M	$14M
Enterprise Value	$-5M	$281M
Price	$1.34	$0.61
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.09x
EV/Sales	0.00x	1.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.75x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	0.32x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.10x
Revenue & Growth
Revenue (TTM)	$0	$147M
Revenue Growth (YoY)	N/A	6.8%
Forward Rev Growth	1211.4%	27.7%
Profitability
Gross Margin (TTM)	0.0%	95.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-56.1%
Net Margin (TTM)	0.0%	-153.3%
FCF Margin (TTM)	N/A	-44.6%
Net Income (TTM)	$-19M	$-225M
FCF (TTM)	$-15M	$-65M
EPS (TTM)	-$0.96	-$7.77
ROE (TTM)	-9118.0%	-18243.0%
ROA (TTM)	-7693.0%	-20094.0%
ROIC (TTM)	-9006.0%	-6632.0%
Financial Health
Cash	$18M	$55M
Debt	$126K	$322M
Net Cash/Debt	$18M	$-267M
Current Ratio (TTM)	8.21x	0.79x
Quick Ratio (TTM)	8.13x	0.71x
Debt/Equity (TTM)	0.01x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.24	1.14
52W Performance	-44.4%	-89.7%
YTD Performance	-45.5%	-91.6%
% from 52W High	-50.9%	-94.5%
% from 52W Low	52.3%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.31x
FCF Yield (TTM)	-110.6%	-476.7%
Earnings Yield (TTM)	-141.4%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View INAB research	View KPTI research